🟢 Neurosense Therapeutics is trading 8% up today on ALS drug submission plans and pipeline optimism

Neurosense Therapeutics is trading at approximately $0.56 (up 8%) as the company continues to see positive momentum from its ALS drug candidate, PrimeC.

• Investors are digesting the July 22 announcement that the company plans to file a New Drug Submission with Health Canada for PrimeC, following strong Phase 2b clinical data reported in late June.
• The stock has stabilized following a period of low-liquidity volatility, supported by a generally bullish environment for biotech and broader U.S. equity markets.